Vepalimomab: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 22:18, 31 December 2020 editOAbot (talk \| contribs)Bots441,761 editsm Open access bot: doi added to citation with #oabot.← Previous edit		Latest revision as of 01:40, 9 April 2023 edit undoEntranced98 (talk \| contribs)Extended confirmed users, Pending changes reviewers, Rollbackers173,243 edits Adding local short description: "Monoclonal antibody", overriding Wikidata description "chemical compound"Tag: Shortdesc helper
Line 1:		Line 1:
			{{Short description\|Monoclonal antibody}}
	{{Drugbox		{{Drugbox
	\| Verifiedfields = changed		\| Verifiedfields = changed

Latest revision as of 01:40, 9 April 2023

Monoclonal antibody Pharmaceutical compound

Vepalimomab
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	VAP-1
Clinical data
ATC code	none
Identifiers
CAS Number	195158-85-1
ChemSpider	none
UNII	0M19J59UH4
(what is this?) (verify)

Vepalimomab is an experimental mouse monoclonal antibody intended for the treatment of inflammations. It blocks vascular adhesion protein 1. Development of the drug was discontinued in 2002.

References

Vainio PJ, Kortekangas-Savolainen O, Mikkola JH, Jaakkola K, Kalimo K, Jalkanen S, Veromaa T (June 2005). "Safety of blocking vascular adhesion protein-1 in patients with contact dermatitis". Basic & Clinical Pharmacology & Toxicology. 96 (6): 429–35. doi:10.1111/j.1742-7843.2005.pto_05.x. PMID 15910406.
"Vepalimomab". AdisInsight. Springer Nature Switzerland AG.

Immunosuppressive drugs / Immunosuppressants (L04)

Intracellular
(initiation)

Antimetabolites

purine synthesis inhibitors
- Azathioprine
- Mycophenolic acid

dihydroorotate dehydrogenase inhibitors
- Leflunomide
- Teriflunomide

antifolate
- Methotrexate

Macrolides/
other IL-2 inhibitors

FKBP/Cyclophilin/Calcineurin

IMiDs

Intracellular
(reception)

IL-1 receptor antagonists	Anakinra
mTOR	Everolimus Ridaforolimus Sirolimus Temsirolimus Umirolimus Zotarolimus

Extracellular

Antibodies

Monoclonal

Serum target
(noncellular)

Complement component 5
- Eculizumab

TNF

Interleukin
- Anakinra
- Basiliximab
- Bimekizumab
- Briakinumab
- Brodalumab
- Canakinumab
- Daclizumab
- Guselkumab
- Ixekizumab
- Netakimab
- Olokizumab
- Rilonacept
- Risankizumab
- Sarilumab
- Satralizumab
- Secukinumab
- Siltuximab
- Sirukumab
- Spesolimab
- Tildrakizumab
- Tocilizumab
- Ustekinumab

Interleukin 5
- Mepolizumab

Immunoglobulin E
- Omalizumab

Interferon
- Faralimomab

IL-6
- Elsilimomab

IL-12, IL-13, and IL-23
- Lebrikizumab
- Ustekinumab

IL-17A
- Secukinumab

Cellular
target

IL-2 receptor/CD25

T-lymphocyte (Zolimomab aritox)

Unsorted

Polyclonal

-cept (Fusion)

CTLA-4
- Abatacept
- Belatacept
TNF inhibitor
- Etanercept
- Opinercept
Aflibercept
Alefacept
Rilonacept

Unsorted

Monoclonal antibodies for the immune system

Immune system

Human	Immunosuppression: Abrilumab Adalimumab Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Golimumab Ianalumab Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab Zanolimumab Combination: Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive: Apolizumab Aselizumab Atezolizumab Benralizumab Camrelizumab Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Frexalimab Inebilizumab Itolizumab Lampalizumab Letolizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140 Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412 Immune activation: Dostarlimab Other: Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab Lebrikizumab Olokizumab Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatory lesions

Mouse	Besilesomab Fanolesomab Lemalesomab Sulesomab

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: